NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Tivozanib for treating recurrent or metastatic renal cell carcinoma

Batch 49

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? No potential equality issues been identified during the scoping process 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? NA 3. Has any change to the draft scope been agreed to highlight potential equality issues? NA 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?		
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? NA 3. Has any change to the draft scope been agreed to highlight potential equality issues? NA 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes	1.	process (draft scope consultation and scoping workshop discussion),
Issues need addressing by the Committee? NA 3. Has any change to the draft scope been agreed to highlight potential equality issues? NA 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes	No po	tential equality issues been identified during the scoping process
Issues need addressing by the Committee? NA 3. Has any change to the draft scope been agreed to highlight potential equality issues? NA 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes		
 3. Has any change to the draft scope been agreed to highlight potential equality issues? NA 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes 	2.	, , , , , , , , , , , , , , , , , , , ,
equality issues? NA 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes	NA	
equality issues? NA 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes		
Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes	3.	
been identified during the scoping process, and, if so, have changes	NA	
been identified during the scoping process, and, if so, have changes		
	4.	been identified during the scoping process, and, if so, have changes

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of tivozanib for

treating recurrent or metastatic renal cell carcinoma

Issue date: February 2017

NA		

Approved by Associate Director (name): Frances Sutcliffe

Date: 12/01/2017

2 of 2